WuxiPRA JV Nabs Ex-Theorem CEO as President

By Zachary Brennan

- Last updated on GMT

WuxiPRA JV Nabs Ex-Theorem CEO as President

Related tags: Contract research organization, Clinical trial

WuXiPRA, the new China-based joint venture between the two CROs, has named contract research veteran James Pusey, MD, as president and general manager.

As the former CEO of Theorem Clinical Research and SVP of MDS Pharma Services, Posey offers the JV more than 25 years of experience including advancements of his previous companies’ Asian businesses.

"His global experience in the CRO market will be an asset to WuXiPRA. With clinical trials continuing to expand in China, having Dr. Pusey onboard will allow us to establish a stronghold in the region​," Colin Shannon, president and CEO, PRA.

The JV announced in January was perceived by some​ as a way for both companies to expand its late-stage services in the region. The companies will offer Phase I-IV services in China, Hong Kong and Macau.

John Kreger, an equity analyst with William Blair, previously said the JV signals WuXi’s intent to be a dominant force in the late-stage sector in China. Kent Thoelke, SVP of PRA, in comments from earlier this year​ confirmed his company’s intentions to do just that, adding that the companies are looking to make the JV the biggest CRO in China within several years.

WuXi’s local expertise and bioanalytical lab experience is expected to combine with PRA’s international late-stage trial experience. Both companies are expected to contribute employees to the JV.

"Under James's leadership, we believe WuXiPRA will become the clinical CRO of choice in China​," Dr. Ge Li, chairman and CEO of WuXi PharmaTech said.

China Troubles

The JV will look to avoid a number of recent issues surrounding the clinical trial landscape in China.  GlaxoSmithKline employees are currently embroiled in a fiasco​ dealing with millions in bribery allegations and supposed sexual favors for increased sales, according to Bloomberg News.

Bristol-Myers Squibb was also recently cited​ for allegedly manipulating data in trials that supported and eventually delayed the approval of its blood thinner Eliquis.  

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars